Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687366 | 0.95 | CTSA (0.37) | SMN1; SMN2ITGB1ITGA4KDM4EALDH1A1 | |
| SCHEMBL688327 | 0.91 | SLC22A12 (0.34) | NOTUMITGB1ITGA4KDM4EALDH1A1 | |
| SCHEMBL688386 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2ITGB1ITGA4KDM4EALDH1A1 | |
| SCHEMBL687907 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2ITGB1ITGA4KDM4EALDH1A1 | |
| SCHEMBL688330 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EALDH1A1CTSAKMT2A | |
| SCHEMBL686989 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2ITGB1ITGA4KDM4EALDH1A1 | |
| SCHEMBL687715 | 0.87 | CTSA (0.39) | SMN1; SMN2ITGB1ITGA4KDM4EALDH1A1 | |
| SCHEMBL687687 | 0.86 | PTGER3 (0.38) | NOTUMITGB1ITGA4SLC22A12 | |
| SCHEMBL687119 | 0.86 | SMN1; SMN2 (0.36) | SMN1; SMN2ITGB1ITGA4KDM4EALDH1A1 | |
| SCHEMBL687631 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4EALDH1A1CTSAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | claimed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | claimed |
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | SMN1; SMN2 2958/4885NOTUM 2235/4885ITGB1 5/4885 |
| US-20040063955-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, FN1 | SMN1; SMN2 2960/4885NOTUM 1823/4885ITGB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.